Yttrium90 radiolabelled antiCD66 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 28 | Systemic amyloidosis | 1 |
28. Systemic amyloidosis
Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-002231-18-GB (EUCTR) | 01/12/2015 | 23/09/2015 | A Phase I/IIa (early phase) Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL Amyloidosis | A Phase I/IIa Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL Amyloidosis - Targeted Radiotherapy for AL-Amyloidosis –‘TRALA’ | AL-Amyloidosis MedDRA version: 18.0;Level: LLT;Classification code 10024460;Term: Light chain disease myeloma associated;System Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04] | Product Name: CHX-A-DTPA-Anti-CD66 INN or Proposed INN: CHX A-DTPA anti-CD66 antibody Product Name: Indium 111 labelled Anti-CD66 INN or Proposed INN: Indium 111-radiolabelled anti-CD66 Product Name: yttrium-90 radiolabelled anti-CD66 antibody INN or Proposed INN: Yttrium90 radiolabelled antiCD66 | University Southampton Hospital NHS Foundation Trust | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 18 | Phase 1/2 | United Kingdom |